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Abstract
Background Service users are increasingly involved in the design
of clinical trials and in product and device development. Service
user involvement in placebo development is crucial to a credible
and acceptable placebo for clinical trials, but such involvement has
not yet been reported.
Aims To enhance the design of a future clinical trial of hand
splints for thumb-base osteoarthritis (OA), service users were
involved in splint selection and design of a placebo splint. This
article describes and reﬂects on this process.
Design Two fora of service users were convened in 2011. Service
users who had been prescribed a thumb splint for thumb-base OA
were approached about involvement by Occupational Therapy
(OT) practitioners.
Content of the fora A total of eight service users took part in the
fora. Service users discussed their experience of OA and their own
splints and then tried a variety of alternative splints. Through this
they identiﬁed the active features of splints alongside acceptable
and unacceptable design features. Service users focused on wear-
ability and support with or without immobilization. Fora discussed
whether a placebo group (‘arm’) was an acceptable feature of a
future trial, and service users developed a potential design for a
placebo splint.
Conclusion and discussion This is the ﬁrst project that to involve
service users in placebo design. Service users are increasingly
involved in product and device design and are ideally placed to
identify features to make a placebo credible yet lacking key
active ingredients. The future trial will include research into its
acceptability.
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Introduction
Clinical trials are central to the production of
evidence informing health-care policy and
delivery.1 Considerable advice exists about how
best to involve members of the public or ser-
vice users in health-related research, including
clinical trials.2–4 A recent literature review
highlights four key areas in which the public
have been involved in clinical trial design:
review of consent procedures and patient infor-
mation, suggestion of additional trial out-
comes, review of data collection procedures
and recommendations about follow-up data
collection.5 Additionally, earlier stages of trial
design necessarily involve speciﬁcation of inter-
ventions to be assessed. This is because the
ultimate aim of clinical trials is usually to iden-
tify which interventions deliver best outcome
for patients and to evaluate the safety and
cost-eﬀectiveness of interventions under investi-
gation. The speciﬁcation of interventions is
therefore crucial, and guidance from the UK’s
Medical Research Council stresses the impor-
tance of involving stakeholders in the develop-
ment of complex interventions.6 To date, this
principle has been applied in the development
of interventions in a variety of health areas,
with critical inﬂuence on trial design.7,8
While evidence of eﬃcacy and safety from
clinical trials is a legal precursor to the release
of any new drug into the market, such evidence
is not required prior to implementation of most
non-pharmacological interventions. However,
with the rise of evidence-based health care or
medicine (EBM),9 clinical trials are increasingly
promoted as the means to secure evidence to
support non-pharmacological interventions. An
increasing number of clinical trials explore
these, including self-management and exercise
packages,10,11 physiotherapy,12 and psychologi-
cal therapies for pain.13 There is also growing
interest in subjecting established interventions
to scrutiny in clinical trials. This accords with
the agenda of EBM, in which evidence from
clinical trials is described as ‘gold standard’,
and also with wider imperatives to maximize
cost-eﬀectiveness of health care. For health
conditions in which a range of interventions
already exist, then identiﬁcation of interven-
tions to include in trials is an early stage of
research design.11
When there is uncertainty about the eﬃcacy
of existing interventions and it is possible that
unintended factors might aﬀect outcome, then
a clinical trial might include a placebo group
(or ‘arm’). In a placebo group, participants
receive an ‘inert’ placebo rather than an ‘active’
intervention; a well-known example of a pla-
cebo would be a pill containing an inert sub-
stance.14 Inclusion of a placebo group within a
trial enables comparison of outcomes in partic-
ipants receiving an active intervention with
outcome in those receiving the placebo. This
indicates whether the intervention or other fac-
tors confer any eﬀect, and there has been much
debate about how to characterize the ‘placebo
response’ and its association with contextual
factors.15–18 Uncertainty about eﬃcacy and the
possibility that factors other than the ‘active’
intervention may be inﬂuencing outcome are
important when making a decision about
whether a placebo-controlled trial is ethical.19
In placebo-controlled trials, trial integrity is
maintained by ensuring that trial participants
do not know whether they received the inter-
vention or placebo until after trial completion:
this is known as ‘blinding’. While maintaining
blinding, participants in placebo-controlled tri-
als should be informed and understand that
there is a chance that they might receive a pla-
cebo. This maintains the principle of informed
consent to research participation. It is therefore
critical that any placebo is credible so that par-
ticipants are not aware that they have received
the placebo, and it is important that inclusion
of a placebo is acceptable to potential research
participants. Even beyond any ethical consider-
ations, placebo-controlled trials are subject of
debate, particularly when placebo groups are
included in non-pharmacological trials. Some
argue that clinical trials including placebo
interventions can provide evidence about
whether the addition of an intervention has an
impact on eﬀectiveness when compared with a
basic intervention.20 Others contend that non-
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pharmaceutical interventions include character-
istic and incidental eﬀects and that this can
lead to false-negative results, particularly in tri-
als of complex interventions.21
Although a small number of studies report
consulting with patients or the public about
whether inclusion of a placebo in a trial is
acceptable,8,22 and examples exist of involving
health professionals in placebo design,22 we
have found no studies that have actively
involved service users in their design. The pro-
ject described here sought to involve service
users in the design of a placebo for inclusion in
a trial alongside their involvement in identiﬁca-
tion of ‘active’ interventions.
Topic area
Our team is working on a project focusing on
osteoarthritis (OA): the leading cause of mus-
culoskeletal pain and disability in adults aged
 50 years. Osteoarthritis aﬀects many joints
in the body, but hand OA places particular
limitations on daily activity and participation
and is associated with pain, reduced strength
and stiﬀness.23,24 Estimating the prevalence of
hand OA presents challenges because of diﬀer-
ences in the nature of information based on
presentation of symptoms, self-report or radio-
graphs (‘x-ray’). Prevalence in adults assessed
by self-report ranges from 4.3 to 6.2%;
assessed by radiograph ranges from 20.6 to
82.6%; and assessed through symptoms ranges
from 2 to 77.1%.25 Much hand OA is located
in the base of the thumb (‘thumb-base OA’),
with the potential to have more lasting pain,
work disability, reduction in quality of life and
overall function than OA in other hand
sites.26,27
With an ageing population and increased life
expectancy, it is important to establish eﬀective
interventions for thumb-base OA. Options for
OA pain and symptom management include
pain relief or anti-inﬂammatory medication,
splints, exercise, topical creams and gels and
surgery.28 However, a recent systematic review
highlights a lack of high-quality evidence on
which to base recommendations for non-phar-
macological therapy of hand OA.29,30 In addi-
tion, health professionals do not necessarily
provide people with hand OA with information
or access to the full range of options.31
As an option for hand OA, splints aim to
provide immobilization, support and pain
relief. In the UK, Occupational Therapists
(OTs) often provide splints to patients with
hand OA, although hand splints are also avail-
able on the open market. Splint design has
evolved over recent years, with the advent of
new materials including thermoplastics, foam
and other materials since the 1960s.32 Hand-
splint designs now include supportive soft
thumb wraps, metal or plastic posts contained
within an elasticated fabric, and ‘hard’ splints
made entirely of plastic, individually heat
moulded to ﬁt.33
Hand splints are widely used and readily
available, although a systematic review of
twelve randomized trials indicated that splints
may reduce OA hand pain, but also high-
lighted that ‘the general evidence of the eﬀect
of splints and exercise in hand OA is still insuf-
ﬁcient’.24 As it is possible that splints may
bring about a degree of placebo response in
their users,15–18 and there is a need to under-
stand the mechanisms through which Occupa-
tional Therapy (OT) intervention may have
eﬀect,34 then a placebo-controlled trial provides
the scope to assess these. By including a pla-
cebo group in a trial that also evaluates a ‘true’
splint, exercise and usual care, a placebo-con-
trolled trial can help to provide evidence to
inform the provision of care for thumb-base
OA, and as yet no studies have included a pla-
cebo splint.
Designing a placebo-controlled trial requires
particular attention, because a placebo needs
to be both credible and acceptable. People
who wear splints for thumb-base OA have
considerable expertise in acceptable design fea-
tures, and these experiences can inform the
design of a placebo splint. We therefore
employed methods of design processes for
medical devices that focus on working with
users. In particular, we employed principles of
participatory design, in which service users and
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professionals work together in design decision
groups (‘fora’) to identify key features of a
device.35,36
This article describes service user involve-
ment in design of a placebo splint and selection
of splints for thumb-base OA. The project will
inform a subsequent Delphi exercise and ran-
domized-controlled trial. We present and reﬂect
on the process, acceptability and value of the
service user involvement project.
The service user involvement project
We conducted a user involvement project
within the development of a protocol for a
pilot randomizedcontrolled trial of splints for
thumb-base OA, funded by Arthritis Research
UK. The project comprised two forum ses-
sions, which were interactive discussion ses-
sions to identify the acceptability of a variety
of designs of hand splints and to design a pla-
cebo hand splint for inclusion in the future
trial.
The two fora were conducted in 2011: ﬁrst
in Bristol, followed by Keele 10 days later. In
Bristol, six women attended the forum, and in
Keele, a man and a woman took part. Their
age ranged between 56 and 72 years. All forum
members had diagnosed thumb-base OA
(recent and longstanding, between 9 months
and 28 years) and had experience of wearing a
hand splint or splints. Potential forum mem-
bers were approached by OTs working within
local hospitals, who identiﬁed patients with
thumb-base OA and provided them with enve-
lopes containing leaﬂets about the project, as
well as reply slips to return to the University
teams should they be interested in coming to a
forum. The leaﬂets provided detail about how
the groups would be run, who would be there
and why the project was needed. We used an
opt-in system, whereby service users were pro-
vided with information and were free to decide
whether they were interested in coming to the
session. We did not record details of anyone
who did not contact the University teams. The
University teams received eight replies and
then contacted potential forum members with
further information about location and practi-
cal arrangements. Each forum lasted three
hours, including refreshments and breaks.
Travel expenses were reimbursed, and group
members were each provided with a £40 shop-
ping voucher and helpline telephone numbers.
All were oﬀered information from
INVOLVE37 about receiving payments. Overall
costs for the project included staﬀ time to plan
and conduct the fora, vouchers, expenses and
refreshments.
The fora were not designed as qualitative
focus groups that would generate potentially
generalizable new knowledge, and in which ser-
vice users would be purposively sampled and
become ‘participants’ in research. Instead, they
were designed to provide a structure within
which researchers and service users could work
together to design key elements of the future
trial. The project took place under the auspices
of existing service user involvement groups at
the Universities of Bristol and Keele within
which service users are partners in the research
process rather than research participants. The
distinction between research and service user
involvement is described in existing literature
and guidance,3 although the diﬀerence has
implications for whether such activities are seen
as generating evidence, which is addressed in
the Discussion.
At the start of each session, the project was
discussed with forum members, who were
asked to sign a form stating that they were
willing to ‘take part in the forum and to keep
conﬁdential the things said today’. They were
also asked if they agreed to be audio-recorded,
for anonymous quotations to be published,
and to future contact.
The fora were designed to be as interactive
as possible and were facilitated by two Uni-
versity research staﬀ (RG-H and JA), one of
whom is also an OT (JA). Also present were
two project Research Fellows at both fora
and a Patient and Public Involvement Coordi-
nator in the Keele forum, who assisted with
practical arrangements and recording the dis-
cussion on audio ﬁle, ﬂip charts and notes
sheets.
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Forum sessions were designed to foster inter-
action and promote collaboration between staﬀ
and forum members and were conversational
and discursive. After a discussion of the study
and introductions, forum members described
their experiences of thumb-base OA and
splints. In these discussions, they talked about
the things that they could or could not do since
having OA, how they obtained their splints,
when they wore them and what they thought
of them.
In the second part of the sessions, facilitators
placed 45 diﬀerent splints on the table. These
splints were all examples of those available
within the UK at the time and were new and
unworn. Splints were chosen to represent a
range of styles and materials (soft, hard, short
and long) and were obtained from OTs and
splint providers. Forum members tried the
splints on and compared them with their own
splints. Facilitators worked with the groups and
engaged with forum members as they tried
splints on. Views about splints were recorded
on ﬂip charts, and facilitators established
whether views were consensus views or those of
individuals. Once forum members had all tried
and commented on a range of splints, facilita-
tors described the rationale behind randomized
trials and the inclusion of a placebo group. The
group discussed their views about the inclusion
of a placebo group in a trial of hand splints
and optimal OT care. After this, the forum
members discussed how a convincing placebo
should look and feel. Forum members were
encouraged to work with materials that might
be used to produce a placebo splint, including
thermoplastic and elasticated material.
At the end of the sessions, forum members
completed evaluation forms. These asked about
levels of satisfaction with the information leaf-
let, venue, how the team ran the forum,
whether their views were taken into account,
whether the forum made decisions about the
types of hand splints and how to design a pla-
cebo splint for use in the ﬁnal research project.
In addition to practical considerations, these
questions were designed to identify whether
forum members felt that their involvement
would impact on the future trial design, to
establish the degree of their involvement. Eval-
uation forms also included free text sections for
forum members to explain their answers and a
space for other comments about the forum.
The groups’ views
In the ﬁrst part of each forum session, service
users spoke about their experiences of living
with thumb-base OA. They described pain and
stiﬀness and loss of strength. Discussion of the
everyday experience of thumb-base OA
included conversation about how forum mem-
bers managed, or felt challenged by, everyday
activities such as housework, driving, garden-
ing and other tasks requiring dexterity and
grip. Some forum members described wearing
their splint everyday, while others said they
would only wear their splint when pain became
‘unbearable’ or when engaging in activity that
required hand support. Support in painful
areas and immobilization were highlighted as
useful. Service users’ experiences provided con-
text for in-depth discussion about splint design
in the second part of forum sessions.
In the second part, facilitators worked with
forum members so that they could try on and
discuss the wide variety of splints. Building on
the previous discussion and comparisons with
forum members’ own splints, this enabled the
identiﬁcation of acceptable and unacceptable
design features. While there was a degree of
consensus about these, there was some varia-
tion in forum members’ views. However, in
general terms, the fora identiﬁed design fea-
tures that can be categorized as wearability or
on type and degree of support and immobiliza-
tion.
Factors that aﬀected wearability included
warmth, colour, material, method of fastening
and washability. Forum members felt that
materials such as neoprene could be too hot in
the summer. Most people disliked the beige
colour of many of the splints, as they felt it
was ‘too medical’ and not a practical colour.
However, one forum member did not see this
as an issue. Many forum members disliked
ª 2013 John Wiley & Sons Ltd Health Expectations, 16, pp.e100–e110
Designing a placebo device, R Gooberman-Hill et al.e104
hard, moulded plastic splints, and thought that
while hook-and-loop fastener (‘Velcro’®,
Middlewich-Cheshire, UK) fastenings were
easy to put on and oﬀ, they caught on cloth-
ing. All forum members were concerned about
whether splints could be washed. Most were
aware of the appearance of splints, and some
felt embarrassed that they represented a public
declaration of their condition and limitations.
Support and immobilization of the aﬀected
joint at the base of the thumb was seen as
crucial. If splints failed to provide these, then
they were considered ineﬀective. Some forum
members demonstrated how they tightly fas-
tened their splints to provide support and oth-
ers discussed how they felt beneﬁt if splints
applied pressure to painful joints that they
might otherwise choose to rub for relief.
Identifying the factors that made hand
splints wearable and eﬀective was a crucial step
in the process of placebo design. In the next
stage of the fora, the materials and design of a
placebo splint were discussed. The idea of a
placebo group was introduced, with the facili-
tators using trials of medication to explain ran-
domization and placebo. The presence of
current uncertainty about best treatments for
thumb-base OA was also addressed. Forum
members discussed the idea of a placebo and
inclusion of a placebo group within the trial.
All thought that these were acceptable ways of
achieving information about best treatments
for thumb-base OA.
Building on views about the active ingredi-
ents of splints, forum members worked on pla-
cebo design. The OT (JA) presented two
possible options for the hard, moulded plastic
elements of a placebo splint that had been
developed in collaboration with other OT.
Alongside the hard, moulded elements, a range
of fabrics that could be used to keep the hard
element in place were made available for the
forum members to work with. These were dis-
cussed, handed round and tried on. Both fora
decided that it was crucial that a placebo splint
did not oﬀer any ‘real’ support for the joint at
the base of the thumb. To achieve this, one of
the hard plastic elements, was better than the
other. The fabrics that the fora worked with
were all supportive, elasticated fabrics in beige.
Colour was seen as important for a placebo’s
credibility, although the words used to describe
it varied. As one forum member explained: ‘the
repulsive ﬂesh/pink colour of the splint would
be convincing’. The forum members handled
the fabrics and worked with the OT to cut
them to size in order to ﬁx the hard support in
place. This was performed to create the ﬁrst
prototype placebo splint, which forum
members tried on. Despite earlier concerns
about damage to clothing, forum members
thought that hook-and-eye fastenings were
appropriate and convincing if they remained
secure. In each forum, the prototype was pho-
tographed as a record, and all agreed that the
placebo design could be based on this idea.
Both fora arrived at broadly similar designs,
the detail of which will be published alongside
future trial ﬁndings to maintain trial blinding.
Discussion and development of the placebo
provided focus for further discussion of blind-
ing. One forum member pointed out that to
retain blinding in the trial, then the study team
should ensure that placebo splint wearers should
not encounter wearers of active splints, which
would be a real possibility at clinics. Forum
members all agreed that this was an issue, partic-
ularly if those individuals discussed their respec-
tive splints and made comparisons about
position, level of support and immobilization.
Reflection on process and results of the
evaluation
In the fora, the activity of trying splints on
engendered discussion about their acceptability
and possible eﬀects. The fora did not necessar-
ily seek to build consensus about opinion based
on experience, but sought to establish where
consensus existed and to debate and discuss
individual diﬀerences. This then enabled deci-
sions to be made about priorities. For instance
in the Bristol forum, one group member felt
that splint colour was not important: she was
comfortable with beige coloured fabric. On bal-
ance, as other group members identiﬁed colour
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as an issue, it was agreed that colour was as
important element of the design of acceptable
splints in the future. Furthermore, colour was
so salient issue for most group members that
all agreed that a credible placebo splint should
be beige.
The two fora had radically diﬀerent numbers
of service users present, with six in Bristol and
two at Keele. In the group of six, the consider-
able interaction between forum members was
relatively unmediated by the facilitators. In the
forum with two service users, forum members
asked each other questions, but in the section
where they tried on a range of splints, the ses-
sions became more individualized as each
forum member had a facilitator working with
them on a one-to-one basis. In both sessions,
care was taken to scribe the input and deci-
sions of forum members onto ﬂip chart paper.
These were fed back and discussed, enabling
clariﬁcation. In both sessions, all members had
the chance to share their experience of OA and
splint wear. There were no noticeable diﬀer-
ences between the contributions of each group,
but additional groups involving more service
users might have generated views that were at
variance with those recorded here. The groups
aimed to serve as platforms for codesign,
rather than to provide representative accounts
of preferences for splints, with a future trial
assessing use and impact of splints in a repre-
sentative sample of the population.
Forum members completed brief evaluation
questionnaires at the end of each session. These
elicited information to inform improvements to
involvement activities in the future, to assess
satisfaction with the decisions made and to
ascertain degree of involvement. All forum
members were ‘very satisﬁed’ that their views
had been taken into account, were ‘satisﬁed’ or
‘very satisﬁed’ that the group had made deci-
sions about splint types to include in a future
project and all were ‘very satisﬁed’ that the
group had made decisions about how to design
a placebo splint. Comments about the sessions
included: ‘very enjoyable, friendly and con-
structive’, ‘there was a good range of samples
[splints] and it was reasonably easy to choose
the ones we preferred and our views were care-
fully noted’, ‘very welcoming and professional
and fun!’ ‘really enjoyable, great to do some-
thing positive, lovely to meet the team’, ‘we
were all listened to and I felt really lucky to be
involved in it all’.
The next phase of the project is a Delphi
study to identify views from clinicians and
patients about optimal intervention. Seven of
the eight forum members will be involved in
the Delphi study. The two fora contribute the
following key issues to the Delphi study: splint
material and any beneﬁts of hard and soft
thumb-base splints, splints issued for diﬀerent
purposes, elements of consultations about
splints, contents of optimal consultations and
follow-up. Design of the randomized trial will
include an ‘optimal OT Package’ and the pla-
cebo group will receive a reﬁned version of the
placebo prototype identiﬁed in the fora.
Discussion
The fora served to inform the design of a
future trial by identifying key features of
splints that made them acceptable and by
working towards a credible placebo splint. The
placebo splint will feature colour, material, fas-
tening and other design features that will make
it credible and acceptable. The design of pla-
cebo devices raises particular challenges,
because a placebo should not contain any of
the active ingredients thought provide beneﬁt.
Additionally, a placebo should not cause harm.
Forum members did not identify any possible
harm that the placebo might cause but did
point out that to retain blinding the trial
design would need to ensure that in clinics,
people wearing placebo splints did not encoun-
ter those with ‘true’ splints. Service users’ expe-
riences of wearing splints made them ideally
positioned to identify features that should be
included in a placebo to make it credible and
yet inactive.
User involvement fora are becoming widely
used as a method of engaging users in health
research. Such group-based activities are often
described as eﬃcient ways of including the
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views and experience of service users within
project design and conduct,38 but it is impor-
tant to evaluate the process. In the hand-splint
project, the forum process was acceptable to
members, with all expressing satisfaction about
how the sessions had led to decisions about the
splints and placebo design. Forum members
were also satisﬁed that their views had been
taken into account. We assessed these aspects
of the fora to identify whether service users felt
that their voices and opinions were heard and
acted upon. Acting upon these is fundamental
to the principle of partnership.
The UK’s National Research Ethics Com-
mittee Service indicates that many planned
clinical trials have no patient or public involve-
ment.39 A recent study found evidence of
involvement in only 31% of UK Medical
Research Council-supported trials, with most
involvement comprising public representation
on steering committees.40 Although this repre-
sents an increase in the proportion of trials
with involvement, the role of the public has
arguably changed little over the last decade.
Ten years ago, public involvement also centred
on steering committee or management group
membership, development of trial protocols
and drafting of information for participants,41
echoeing Boote’s more recent ﬁndings.5
Agreement among professionals that there is
‘equipoise’ or uncertainty about best treatment
is key to the design of ethical trials.42 Allied to
this, representation of people who represent
the trial population in discussions about inclu-
sion of a placebo group has the potential to
maximize appropriateness of ﬁnal trial design.
Previous studies have involved stakeholders,
including patients, in decisions about whether
or not to include placebos in trials. These indi-
cate that the acceptability of placebo inclusion
may be condition and treatment-speciﬁc. For
instance, in Marsden et al.8 report of qualita-
tive research within the design of a trial about
breast cancer treatments, women with breast
cancer preferred that a trial of Hormone
Replacement Therapy (HRT) would not have a
placebo group as they wanted participants to
know during the trial if they were taking HRT.
Women also stressed the importance of quality
of life as a trial end point, but without a pla-
cebo group the authors state that a quality of
life analysis would be ‘diﬃcult’. Campbell
et al.22 found that the idea of a placebo-con-
trolled trial of knee surgery was acceptable to
members of the UK charity Arthritis Care and
to people on waiting lists for surgery. In our
hand-splint project, forum members were intro-
duced to the idea of randomization and pla-
cebo-controlled trial. All thought that a
placebo group was an acceptable option. How-
ever, we must acknowledge that we did not dis-
cuss in any real detail the available evidence
about hand splints, which had led the study
team to conclude that a placebo group would
be valuable. It is possible that stakeholder
involvement even earlier on in the development
of the project could have led to more detailed
discussion around the need for a placebo. Fur-
thermore, we are aware that the fora were not
conducted independently and we could have
strived to widen participation. As the forum in
Keele only comprised two individuals, this had
rather diﬀerent dynamics compared with Bris-
tol; however, both led to eﬀective involvement
as described previously. More generally,
broader questions remain about how best to
involve service users in decisions about the
value and necessity of the inclusion of placebo
groups in trials.
In parallel to the growing imperative to
involve service users in research design, user
groups have been increasingly employed to
good eﬀect in product design (including medi-
cal devices) within commercial and non-com-
mercial settings spanning medical, industrial
and domestic design. Within medical device
design and development, the views of service
users have provided insight into areas of unmet
need, for example in wound care.36 Current
pathways for medical device development rec-
ommend the involvement of ‘end users’ from
such early stages, through to process of design
and reﬁnements of those devices.35 Involvement
of service users in placebo design is an example
of these principles, and in the project described
here, service users were satisﬁed that they have
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contributed to design decisions. Further
research is needed into impact of such activity
on trial conduct and ﬁndings.
We believe that this project represents the
ﬁrst time that service users other than health
professionals have been actively involved in the
design of placebo devices for a randomized
clinical trial, yet their involvement is crucial in
making a placebo device acceptable and credi-
ble. While it may be that this is taking place,
but is unreported, it has been suggested that
good quality reporting of public and patient
activity is needed to ensure eﬀective evaluation
of such work.43 If a clinical trial is considered
necessary to generate evidence in a landscape
of evidence-based medicine and practice, and if
trial participants consent to participation with
this knowledge, then researchers have a duty to
ensure that any placebo is as appropriate and
acceptable as possible.
It is important to note here that the sampling
processes used for service user involvement
activities, and the methods of analysis, are not
intended to lead to research results. This is
because the information collected is not sub-
jected to rigorous qualitative analysis processes,
and because although approaches to service user
involvement often aim to achieve some diversity
of experience they do not aim to achieve ‘satura-
tion’. Instead, user involvement activities pro-
vide practical ways of enabling service user
involvement to input into study design, and at
the heart of involvement activities is the idea
that researchers work ‘with’ service users rather
than conducting research ‘on’, ‘about’ or ‘for’
them.3,44 Finding out about service user views
about OA and splint wear could have been con-
ducted as a qualitative research project, but the
use of product design approaches was itself par-
ticipatory in nature and places service users as
vital partners in the research process, leading
onto a future Delphi study. However, it would
be fair to say that the participatory nature of
the fora is relatively similar to methods of par-
ticipatory action research45 and sought to work
in partnership with service users. Participatory
research designs are one way to bridge the gap
between qualitative research and service user
involvement.46 If projects were to use participa-
tory research methods, this would also enable
researchers to write up their ﬁndings as
‘research’. This is important within a context in
which ﬁndings that are seen as ‘evidence’ have
potential to impact on decisions about policy
and services.1
Forum members thought that the inclusion
of a placebo was appropriate and acceptable
and were conﬁdent that the placebo could be
credible. However, forum membership was not
intended to represent all patients who use
splints, and we do not know how the placebo
splint will be viewed when provided to patients
in clinics within the future trial. Therefore, it
will be important to assess and explore partici-
pants’ views about the acceptability of the pla-
cebo and trial design in a pilot phase of the
future trial. This might be achieved through
participatory research methods.
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